"The
Report PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis
- Global Drug Forecast and Market Analysis to 2022 - Event-Driven
Update provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
The
lupus therapeutics market is dominated by generics and
GlaxoSmithKlines Benlysta is the only drug that has gained marketing
approval for SLE in more than 50 years. Following Benlystas launch,
patients uptake has remained low, but due to its associated high
price-tag Benlysta has managed to grow the lupus market in terms of
value and is currently the top-selling drug in this market, having
generated approximately $265.6m in 2014 in the seven major markets.
There is high R&D activity for the development of new therapies
for lupus and seven promising biological therapies have the potential
to enter the SLE and LN market during the 2012-2022 forecast period.
The introduction of new biologic drugs will shape the future
competitive landscape and drive growth in the SLE and LN markets.
View Report At
:http://www.marketresearchreports.biz/analysis/277394
Highlights
Key Questions Answered
- What was the impact of Benlysta on the lupus therapeutics market following its approval in 2011 and what is its future outlook in this market?
- What do physicians think about Rituxan following its unsuccessful Phase III trials in LN, and how will it be used off-label in lupus during the forecast period?
- What is the significance of late-phase pipeline products and how will their launch shape the future treatment landscape in SLE and LN?
- What are the significant unmet needs in the SLE and LN markets?
- What are the remaining opportunities in the SLE and LN markets?
Key Findings
- The key drivers of growth for the SLE and LN markets are the increasing uptake of GlaxoSmithKlines Benlysta, the potential launch of new biologic drugs and the increasing number of prevalent cases of SLE and LN during the 2012-2022 forecast period.
- R&D strategies include the development of me-too and first-in-class therapies, partnerships and acquisitions, and the development of products for LN.
- The lupus therapeutics market is characterized by significant unmet needs. The most pressing unmet need is the development of new therapies that will offer potent clinical benefits, have a positive safety profile and increase the available treatment options for patients.
Download
Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/277394
Scope
- Overview of SLE and LN, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
- Annualized SLE and LN therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the SLE and LN therapeutics markets.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs.
- Analysis of the current and future market competition in the global SLE and LN therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
- Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global SLE and LN therapeutics markets.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SLE and LN therapeutics markets in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global SLE and LN therapeutics markets from 2012-2022.
- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 16
1.2 List of Figures 22
2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 25
2.3 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Etiology and
Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 28
3.2 Prognosis 29
3.3 Quality of Life 29
3.4 Symptoms 30
4 Epidemiology 31
4.1 Risk Factors and
Comorbidities 31
4.1.1 Women are at a higher
risk of developing SLE than men 31
4.1.2 Caucasians are at lower
risk of developing SLE than other ethnicities 32
4.1.3 Familial history has been
associated with an increased risk of developing SLE 33
4.1.4 Certain occupational and
environmental exposures trigger SLE 34
4.2 Global Trends 35
4.2.1 US 36
4.2.2 5EU 37
4.2.3 Japan 40
4.3 Forecast Methodology 40
4.4 Sources Used 42
4.4.1 US 42
4.4.2 France 44
4.4.3 Germany 44
4.4.4 Italy 44
4.4.5 Spain 45
4.4.6 UK 45
4.4.7 Japan 46
4.5 Sources Not Used 47
4.5.1 US 47
4.5.2 5EU 47
4.5.3 Japan 48
4.6 Forecast Assumptions and
Methods 48
4.6.1 US 49
4.6.2 5EU 49
4.6.3 Japan 52
4.7 Epidemiological Forecast of
SLE (2012-2022) 53
4.7.1 Diagnosed Prevalent Cases
of SLE 53
4.7.2 Age-Specific Prevalent
Cases of SLE 55
4.7.3 Sex-Specific Prevalent
Cases of Diagnosed SLE 57
4.7.4 Age-Standardized
Prevalence of SLE 58
4.7.5 Diagnosed Prevalent Cases
of LN 59
4.7.6 Prevalent Cases of LN,
Segmented by Class 61
4.8 Discussion 63
4.8.1 Conclusions on
Epidemiology Trends 63
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment